27697751|t|MiR-495 functions as an adjuvant to radiation therapy by reducing the radiation-induced bystander effect
27697751|a|The radiation-induced bystander effect (RIBE) is an important factor in tumor radiation therapy because it may increase the probability of normal cellular injury and the likelihood of secondary cancers after radiotherapy. Here, we identified the role of miR-495 in alleviating RIBEs during radiotherapy. Luciferase reporter assay results confirmed that miR-495 regulated endothelial nitric oxide synthase (eNOS) by targeting the Sp1 3'-untranslated region. Consequently, after radiation, tumor cells expressed less eNOS and Sp1 than controls. In vitro cell irradiation data based on flow-cytometric analysis and enzymed linked immunosorbent assay confirmed that nitric oxide (NO) and its downstream product transforming growth factor β1 (TGF-β1) were critical signaling factors contributing to RIBEs. Fewer normal LO2 liver cells were injured and fewer micronuclei were observed when treated with the medium of the miR-495 overexpressing HepG2 and ZR75-1 tumor cells. Accordingly, treatment with the miR-495 antagomir led to higher NO and TGF-β1 levels and more injured LO2 cells. In vivo experiments indicated that local irradiation of tumors overexpressing miR-495 produced fewer necrotic foci in non-irradiated liver tissue compared with controls. miR-495 was upregulated in clinical cancer tissues compared with adjacent non-cancerous tissues, and radiation significantly reduced the expression level of miR-495 in carcinoma cell lines. In summary, miR-495 may have promise as an adjuvant for tumor radiation therapy to decrease RIBEs involving the Sp1 / eNOS pathway.
27697751	0	7	MiR-495	T017	UMLS:C1826049
27697751	8	17	functions	T038	UMLS:C0314627
27697751	36	53	radiation therapy	T058	UMLS:C1522449
27697751	70	104	radiation-induced bystander effect	T038	UMLS:C0949629
27697751	109	143	radiation-induced bystander effect	T038	UMLS:C0949629
27697751	145	149	RIBE	T038	UMLS:C0949629
27697751	177	182	tumor	T038	UMLS:C0027651
27697751	183	200	radiation therapy	T058	UMLS:C1522449
27697751	289	306	secondary cancers	T038	UMLS:C0027627
27697751	313	325	radiotherapy	T058	UMLS:C1522449
27697751	359	366	miR-495	T017	UMLS:C1826049
27697751	382	387	RIBEs	T038	UMLS:C0949629
27697751	395	407	radiotherapy	T058	UMLS:C1522449
27697751	409	434	Luciferase reporter assay	T058	UMLS:C0005507
27697751	443	452	confirmed	T033	UMLS:C0750484
27697751	458	465	miR-495	T017	UMLS:C1826049
27697751	476	509	endothelial nitric oxide synthase	T103	UMLS:C0669365
27697751	511	515	eNOS	T103	UMLS:C0669365
27697751	534	537	Sp1	T103	UMLS:C0080245
27697751	538	560	3'-untranslated region	T082	UMLS:C0600600
27697751	593	604	tumor cells	T017	UMLS:C0597032
27697751	605	614	expressed	T038	UMLS:C1171362
27697751	620	624	eNOS	T103	UMLS:C0669365
27697751	629	632	Sp1	T103	UMLS:C0080245
27697751	688	712	flow-cytometric analysis	T062	UMLS:C0936012
27697751	717	751	enzymed linked immunosorbent assay	T058	UMLS:C0014441
27697751	752	761	confirmed	T033	UMLS:C0750484
27697751	767	779	nitric oxide	T103	UMLS:C0028128
27697751	781	783	NO	T103	UMLS:C0028128
27697751	793	803	downstream	T082	UMLS:C0522506
27697751	812	841	transforming growth factor β1	T103	UMLS:C1704256
27697751	843	849	TGF-β1	T103	UMLS:C1704256
27697751	865	874	signaling	T038	UMLS:C3537152
27697751	899	904	RIBEs	T038	UMLS:C0949629
27697751	919	934	LO2 liver cells	T017	UMLS:C0227525
27697751	958	969	micronuclei	T033	UMLS:C0026004
27697751	1020	1027	miR-495	T017	UMLS:C1826049
27697751	1028	1042	overexpressing	T038	UMLS:C0017262
27697751	1043	1048	HepG2	T017	UMLS:C2717940
27697751	1053	1059	ZR75-1	T017	UMLS:C0007634
27697751	1060	1071	tumor cells	T017	UMLS:C0597032
27697751	1086	1095	treatment	T058	UMLS:C0087111
27697751	1105	1112	miR-495	T017	UMLS:C1826049
27697751	1113	1122	antagomir	T103	UMLS:C4277666
27697751	1137	1139	NO	T103	UMLS:C0028128
27697751	1144	1150	TGF-β1	T103	UMLS:C1704256
27697751	1175	1184	LO2 cells	T017	UMLS:C0227525
27697751	1186	1193	In vivo	T082	UMLS:C1515655
27697751	1194	1205	experiments	T062	UMLS:C0681814
27697751	1206	1215	indicated	T033	UMLS:C1444656
27697751	1242	1248	tumors	T038	UMLS:C0027651
27697751	1249	1263	overexpressing	T038	UMLS:C0017262
27697751	1264	1271	miR-495	T017	UMLS:C1826049
27697751	1287	1300	necrotic foci	T038	UMLS:C0333504
27697751	1304	1331	non-irradiated liver tissue	T017	UMLS:C0736268
27697751	1356	1363	miR-495	T017	UMLS:C1826049
27697751	1368	1379	upregulated	T038	UMLS:C0041904
27697751	1392	1398	cancer	T038	UMLS:C0006826
27697751	1399	1406	tissues	T017	UMLS:C0040300
27697751	1421	1429	adjacent	T082	UMLS:C0205117
27697751	1430	1451	non-cancerous tissues	T017	UMLS:C0040300
27697751	1513	1520	miR-495	T017	UMLS:C1826049
27697751	1524	1544	carcinoma cell lines	T017	UMLS:C0596890
27697751	1549	1556	summary	T170	UMLS:C1706244
27697751	1558	1565	miR-495	T017	UMLS:C1826049
27697751	1602	1607	tumor	T038	UMLS:C0027651
27697751	1608	1625	radiation therapy	T058	UMLS:C1522449
27697751	1638	1643	RIBEs	T038	UMLS:C0949629
27697751	1658	1661	Sp1	T103	UMLS:C0080245
27697751	1664	1668	eNOS	T103	UMLS:C0669365
27697751	1669	1676	pathway	T038	UMLS:C1704259